Risk factors for HIT development during heparin therapy.
\\n\\n
Released this past November, the list is based on data collected from the Web of Science and highlights some of the world’s most influential scientific minds by naming the researchers whose publications over the previous decade have included a high number of Highly Cited Papers placing them among the top 1% most-cited.
\\n\\nWe wish to congratulate all of the researchers named and especially our authors on this amazing accomplishment! We are happy and proud to share in their success!
\\n"}]',published:!0,mainMedia:null},components:[{type:"htmlEditorComponent",content:'IntechOpen is proud to announce that 179 of our authors have made the Clarivate™ Highly Cited Researchers List for 2020, ranking them among the top 1% most-cited.
\n\nThroughout the years, the list has named a total of 252 IntechOpen authors as Highly Cited. Of those researchers, 69 have been featured on the list multiple times.
\n\n\n\nReleased this past November, the list is based on data collected from the Web of Science and highlights some of the world’s most influential scientific minds by naming the researchers whose publications over the previous decade have included a high number of Highly Cited Papers placing them among the top 1% most-cited.
\n\nWe wish to congratulate all of the researchers named and especially our authors on this amazing accomplishment! We are happy and proud to share in their success!
\n'}],latestNews:[{slug:"stanford-university-identifies-top-2-scientists-over-1-000-are-intechopen-authors-and-editors-20210122",title:"Stanford University Identifies Top 2% Scientists, Over 1,000 are IntechOpen Authors and Editors"},{slug:"intechopen-authors-included-in-the-highly-cited-researchers-list-for-2020-20210121",title:"IntechOpen Authors Included in the Highly Cited Researchers List for 2020"},{slug:"intechopen-maintains-position-as-the-world-s-largest-oa-book-publisher-20201218",title:"IntechOpen Maintains Position as the World’s Largest OA Book Publisher"},{slug:"all-intechopen-books-available-on-perlego-20201215",title:"All IntechOpen Books Available on Perlego"},{slug:"oiv-awards-recognizes-intechopen-s-editors-20201127",title:"OIV Awards Recognizes IntechOpen's Editors"},{slug:"intechopen-joins-crossref-s-initiative-for-open-abstracts-i4oa-to-boost-the-discovery-of-research-20201005",title:"IntechOpen joins Crossref's Initiative for Open Abstracts (I4OA) to Boost the Discovery of Research"},{slug:"intechopen-hits-milestone-5-000-open-access-books-published-20200908",title:"IntechOpen hits milestone: 5,000 Open Access books published!"},{slug:"intechopen-books-hosted-on-the-mathworks-book-program-20200819",title:"IntechOpen Books Hosted on the MathWorks Book Program"}]},book:{item:{type:"book",id:"9172",leadTitle:null,fullTitle:"Current Cancer Treatment",title:"Current Cancer Treatment",subtitle:null,reviewType:"peer-reviewed",abstract:"This book is a collection of in-depth chapters on many aspects of contemporary cancer treatment. Written by experts worldwide, each chapter provides a detailed summary of the state-of-the art knowledge in the area, with extensive references and clear and informative diagrams. The volume is divided into two sections: “Basic Science” and “Clinical Challenges.” The five chapters in the first section cover MicroRNA, the role of angiogenesis in the tumor microenvironment, microbial metabolites in the gastrointestinal microenvironment, the role of dendritic cells in anti-tumor immunity, and challenges of current cancer biomarkers. The two chapters in the second section cover pediatric CNS tumors and the role of sentinel node biopsy in endometrial cancer. The information in this book is designed for cancer clinicians and interested readers to whom this knowledge is important for focusing research and improving patient outcomes.",isbn:"978-1-78985-968-3",printIsbn:"978-1-78985-967-6",pdfIsbn:"978-1-83880-998-0",doi:"10.5772/intechopen.83168",price:119,priceEur:129,priceUsd:155,slug:"current-cancer-treatment",numberOfPages:216,isOpenForSubmission:!1,isInWos:null,hash:"c8b318b3a8c31c386efa132b578a70a8",bookSignature:"Mirjana Rajer and Eva Segelov",publishedDate:"June 24th 2020",coverURL:"https://cdn.intechopen.com/books/images_new/9172.jpg",numberOfDownloads:1796,numberOfWosCitations:0,numberOfCrossrefCitations:3,numberOfDimensionsCitations:3,hasAltmetrics:0,numberOfTotalCitations:6,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"March 18th 2019",dateEndSecondStepPublish:"September 17th 2019",dateEndThirdStepPublish:"November 16th 2019",dateEndFourthStepPublish:"February 4th 2020",dateEndFifthStepPublish:"April 4th 2020",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6",editedByType:"Edited by",kuFlag:!1,editors:[{id:"194329",title:"Ph.D.",name:"Mirjana",middleName:null,surname:"Rajer",slug:"mirjana-rajer",fullName:"Mirjana Rajer",profilePictureURL:"https://mts.intechopen.com/storage/users/194329/images/system/194329.jpeg",biography:"Assistant Professor Mirjana Rajer, MD, PhD, graduated from the Faculty of Medicine at the University of Ljubljana in 2001. For two years, she worked at the University Clinic Golnik, Slovenia. Currently, she works at the Institute of Oncology Ljubljana. Her main clinical work consists of treatment of lung cancer and mesothelioma patients. She is also involved as principal and co-investigator in several clinical trials of lung cancer, palliative care, and communication with cancer patients. She serves as an editor for national and international journals and is author of numerous published papers, book chapters, and books. Being a student mentor, Dr. Rajer is actively involved in education. She is an active member of the European Organisation for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), International Association for the Study of Lung Cancer (IASLC), and the Central European Initiative against Lung Cancer.",institutionString:"University Clinic of Pulmonary and Allergic Diseases Golnik",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"2",institution:{name:"Institute of Oncology Ljubljana",institutionURL:null,country:{name:"Slovenia"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:{id:"235057",title:"Prof.",name:"Eva",middleName:null,surname:"Segelov",slug:"eva-segelov",fullName:"Eva Segelov",profilePictureURL:"https://mts.intechopen.com/storage/users/235057/images/system/235057.jpg",biography:"Eva Segelov, MBBS, PhD, FRACP, is Professor of Medicine at Monash University and Director of Oncology at Monash Health, Melbourne, Australia. She is a practicing medical oncologist with more than 20 years’ experience, specializing in gastrointestinal cancer and neuroendocrine tumors, with an international reputation in clinical trials and translational research. Professor Segelov is a board member of the Australasian Gastrointestinal Trials Group; Gastrointestinal Chair of the Clinical Oncology Society of Australia; European Society of Medical Oncology faculty member for the CUP, Endocrine Tumours, and Others group; co-founder of the Commonwealth Neuroendocrine Tumour Society (CommNETS); Associate Editor of Journal of Global Oncology and a cancer editor for the Journal of Visualized Experiments. She heads a translational research laboratory specializing in interrogating clinical trial biospecimens. Professor Segelov has published more than 150 articles, expert reviews and book chapters and is a frequent invited speaker at national and international conferences. She is a member of the Australasian L\\'Oréal-UNESCO for Women in Science jury.",institutionString:"Monash University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Monash University",institutionURL:null,country:{name:"Australia"}}},coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"428",title:"Cancer Biology",slug:"biochemistry-genetics-and-molecular-biology-oncology-cancer-biology"}],chapters:[{id:"70898",title:"MicroRNA: A Signature for Cancer Diagnostics",doi:"10.5772/intechopen.90063",slug:"microrna-a-signature-for-cancer-diagnostics",totalDownloads:250,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Ayesha Siddiqua, Sumaira Kousar, Amer Jamil, Riaz Tabassum, Tariq Mehmood and Nusrat Shafiq",downloadPdfUrl:"/chapter/pdf-download/70898",previewPdfUrl:"/chapter/pdf-preview/70898",authors:[null],corrections:null},{id:"70126",title:"Angiogenesis and Its Role in the Tumour Microenvironment: A Target for Cancer Therapy",doi:"10.5772/intechopen.89667",slug:"angiogenesis-and-its-role-in-the-tumour-microenvironment-a-target-for-cancer-therapy",totalDownloads:237,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Sophia Frentzas, Caroline Lum and Ting-Yu Chen",downloadPdfUrl:"/chapter/pdf-download/70126",previewPdfUrl:"/chapter/pdf-preview/70126",authors:[null],corrections:null},{id:"68417",title:"The Influence of Microbial Metabolites in the Gastrointestinal Microenvironment on Anticancer Immunity",doi:"10.5772/intechopen.88137",slug:"the-influence-of-microbial-metabolites-in-the-gastrointestinal-microenvironment-on-anticancer-immuni",totalDownloads:368,totalCrossrefCites:2,totalDimensionsCites:2,signatures:"Silke Neumann, Estelle M. Peyroux, Matt J. Woodall, Nick J. Shields, Sarah L. Young and Sharon T. Pattison",downloadPdfUrl:"/chapter/pdf-download/68417",previewPdfUrl:"/chapter/pdf-preview/68417",authors:[null],corrections:null},{id:"71516",title:"Dendritic Cells and Their Roles in Anti-Tumour Immunity",doi:"10.5772/intechopen.91692",slug:"dendritic-cells-and-their-roles-in-anti-tumour-immunity",totalDownloads:263,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Ee Shan Pang, Christophe Macri, Timothy Patton, Mariam Bafit and Meredith O’Keeffe",downloadPdfUrl:"/chapter/pdf-download/71516",previewPdfUrl:"/chapter/pdf-preview/71516",authors:[null],corrections:null},{id:"69779",title:"What Are the New Challenges of the Current Cancer Biomarkers?",doi:"10.5772/intechopen.89976",slug:"what-are-the-new-challenges-of-the-current-cancer-biomarkers-",totalDownloads:210,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Jie Chen, Liqiong Yang, Yuxi Duan, Tinging Pu, Sha Zheng, Fangfang Liu, Kun Huang, Greg Mirt and Fan Xu",downloadPdfUrl:"/chapter/pdf-download/69779",previewPdfUrl:"/chapter/pdf-preview/69779",authors:[null],corrections:null},{id:"68805",title:"An Overview of Pediatric CNS Malignancies",doi:"10.5772/intechopen.88189",slug:"an-overview-of-pediatric-cns-malignancies",totalDownloads:166,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Neha Sharma and Deepti Sharma",downloadPdfUrl:"/chapter/pdf-download/68805",previewPdfUrl:"/chapter/pdf-preview/68805",authors:[{id:"244342",title:"Dr.",name:"Deepti",surname:"Sharma",slug:"deepti-sharma",fullName:"Deepti Sharma"},{id:"255595",title:"Dr.",name:"Neha",surname:"Sharma",slug:"neha-sharma",fullName:"Neha Sharma"}],corrections:null},{id:"70283",title:"Role of Sentinel Node Biopsy in Endometrial Cancer",doi:"10.5772/intechopen.89949",slug:"role-of-sentinel-node-biopsy-in-endometrial-cancer",totalDownloads:308,totalCrossrefCites:1,totalDimensionsCites:1,signatures:"Begoña Díaz de la Noval",downloadPdfUrl:"/chapter/pdf-download/70283",previewPdfUrl:"/chapter/pdf-preview/70283",authors:[null],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},relatedBooks:[{type:"book",id:"6589",title:"Smoking Prevention and Cessation",subtitle:null,isOpenForSubmission:!1,hash:"3027e9088771d92f60efe13c5460fef7",slug:"smoking-prevention-and-cessation",bookSignature:"Mirjana Rajer",coverURL:"https://cdn.intechopen.com/books/images_new/6589.jpg",editedByType:"Edited by",editors:[{id:"194329",title:"Ph.D.",name:"Mirjana",surname:"Rajer",slug:"mirjana-rajer",fullName:"Mirjana Rajer"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5793",title:"Novel Implications of Exosomes in Diagnosis and Treatment of Cancer and Infectious Diseases",subtitle:null,isOpenForSubmission:!1,hash:"24e328fe01c47071f2ea44b2608e824f",slug:"novel-implications-of-exosomes-in-diagnosis-and-treatment-of-cancer-and-infectious-diseases",bookSignature:"Jin Wang",coverURL:"https://cdn.intechopen.com/books/images_new/5793.jpg",editedByType:"Edited by",editors:[{id:"188127",title:"Prof.",name:"Jin",surname:"Wang",slug:"jin-wang",fullName:"Jin Wang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7250",title:"Cancer Survivorship",subtitle:null,isOpenForSubmission:!1,hash:"cf8054394c93ff635e50eb4ac8cc8d3a",slug:"cancer-survivorship",bookSignature:"Dil Afroze",coverURL:"https://cdn.intechopen.com/books/images_new/7250.jpg",editedByType:"Edited by",editors:[{id:"244441",title:"Prof.",name:"Dil",surname:"Afroze",slug:"dil-afroze",fullName:"Dil Afroze"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7015",title:"Translational Research in Cancer",subtitle:null,isOpenForSubmission:!1,hash:"cb3276a0256cf8258f16ca0a61386cde",slug:"translational-research-in-cancer",bookSignature:"Sivapatham Sundaresan and Yeun-Hwa Gu",coverURL:"https://cdn.intechopen.com/books/images_new/7015.jpg",editedByType:"Edited by",editors:[{id:"187272",title:"Dr.",name:"Sivapatham",surname:"Sundaresan",slug:"sivapatham-sundaresan",fullName:"Sivapatham Sundaresan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8002",title:"Tumor Progression and Metastasis",subtitle:null,isOpenForSubmission:!1,hash:"db17b0fe0a9b6e80ff02b81a93bafa4e",slug:"tumor-progression-and-metastasis",bookSignature:"Ahmed Lasfar and Karine Cohen-Solal",coverURL:"https://cdn.intechopen.com/books/images_new/8002.jpg",editedByType:"Edited by",editors:[{id:"32546",title:"Dr.",name:"Ahmed",surname:"Lasfar",slug:"ahmed-lasfar",fullName:"Ahmed Lasfar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8211",title:"Squamous Cell Carcinoma",subtitle:"Hallmark and Treatment Modalities",isOpenForSubmission:!1,hash:"e63d63ba8635c79e016991a3047f77d1",slug:"squamous-cell-carcinoma-hallmark-and-treatment-modalities",bookSignature:"Hamid Elia Daaboul",coverURL:"https://cdn.intechopen.com/books/images_new/8211.jpg",editedByType:"Edited by",editors:[{id:"214249",title:"Prof.",name:"Hamid",surname:"Daaboul",slug:"hamid-daaboul",fullName:"Hamid Daaboul"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7054",title:"Current Trends in Cancer Management",subtitle:null,isOpenForSubmission:!1,hash:"0232a5ce1df00d20fe0f0189595886e4",slug:"current-trends-in-cancer-management",bookSignature:"Liliana Streba, Dan Ionut Gheonea and Michael Schenker",coverURL:"https://cdn.intechopen.com/books/images_new/7054.jpg",editedByType:"Edited by",editors:[{id:"92199",title:"Dr.",name:"Liliana",surname:"Streba",slug:"liliana-streba",fullName:"Liliana Streba"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7281",title:"Oncogenes and Carcinogenesis",subtitle:null,isOpenForSubmission:!1,hash:"728df4ace35f652725e5b94da45d0c4d",slug:"oncogenes-and-carcinogenesis",bookSignature:"Pinar Erkekoglu",coverURL:"https://cdn.intechopen.com/books/images_new/7281.jpg",editedByType:"Edited by",editors:[{id:"109978",title:"Prof.",name:"Pınar",surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6813",title:"Cancer Prognosis",subtitle:null,isOpenForSubmission:!1,hash:"003e408f4cf707dd4bbf3332fe49eeb0",slug:"cancer-prognosis",bookSignature:"Guy-Joseph Lemamy",coverURL:"https://cdn.intechopen.com/books/images_new/6813.jpg",editedByType:"Edited by",editors:[{id:"182568",title:"Dr.",name:"Guy-Joseph",surname:"Lemamy",slug:"guy-joseph-lemamy",fullName:"Guy-Joseph Lemamy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6313",title:"Neoplasm",subtitle:null,isOpenForSubmission:!1,hash:"dfea745f8ae5593e6dfc35d9e621291f",slug:"neoplasm",bookSignature:"Hafiz Naveed Shahzad",coverURL:"https://cdn.intechopen.com/books/images_new/6313.jpg",editedByType:"Edited by",editors:[{id:"180702",title:"Dr.",name:"Hafiz",surname:"Shahzad",slug:"hafiz-shahzad",fullName:"Hafiz Shahzad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"72181",slug:"corrigendum-to-potassium-channels-as-a-potential-target-spot-for-drugs",title:"Corrigendum to: Potassium Channels as a Potential Target Spot for Drugs",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/72181.pdf",downloadPdfUrl:"/chapter/pdf-download/72181",previewPdfUrl:"/chapter/pdf-preview/72181",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/72181",risUrl:"/chapter/ris/72181",chapter:{id:"71907",slug:"potassium-channels-as-a-potential-target-spot-for-drugs",signatures:"Vladimir Djokic and Radmila Novakovic",dateSubmitted:"October 13th 2019",dateReviewed:"March 18th 2020",datePrePublished:"April 28th 2020",datePublished:"December 16th 2020",book:{id:"10143",title:"Molecular Pharmacology",subtitle:null,fullTitle:"Molecular Pharmacology",slug:"molecular-pharmacology",publishedDate:"December 16th 2020",bookSignature:"Angel Catala and Usama Ahmad",coverURL:"https://cdn.intechopen.com/books/images_new/10143.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"196544",title:"Prof.",name:"Angel",middleName:null,surname:"Catala",slug:"angel-catala",fullName:"Angel Catala"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"313382",title:"Ph.D.",name:"Radmila",middleName:null,surname:"Novakovic",fullName:"Radmila Novakovic",slug:"radmila-novakovic",email:"radmila.novakovic@med.bg.ac.rs",position:null,institution:null}]}},chapter:{id:"71907",slug:"potassium-channels-as-a-potential-target-spot-for-drugs",signatures:"Vladimir Djokic and Radmila Novakovic",dateSubmitted:"October 13th 2019",dateReviewed:"March 18th 2020",datePrePublished:"April 28th 2020",datePublished:"December 16th 2020",book:{id:"10143",title:"Molecular Pharmacology",subtitle:null,fullTitle:"Molecular Pharmacology",slug:"molecular-pharmacology",publishedDate:"December 16th 2020",bookSignature:"Angel Catala and Usama Ahmad",coverURL:"https://cdn.intechopen.com/books/images_new/10143.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"196544",title:"Prof.",name:"Angel",middleName:null,surname:"Catala",slug:"angel-catala",fullName:"Angel Catala"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"313382",title:"Ph.D.",name:"Radmila",middleName:null,surname:"Novakovic",fullName:"Radmila Novakovic",slug:"radmila-novakovic",email:"radmila.novakovic@med.bg.ac.rs",position:null,institution:null}]},book:{id:"10143",title:"Molecular Pharmacology",subtitle:null,fullTitle:"Molecular Pharmacology",slug:"molecular-pharmacology",publishedDate:"December 16th 2020",bookSignature:"Angel Catala and Usama Ahmad",coverURL:"https://cdn.intechopen.com/books/images_new/10143.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"196544",title:"Prof.",name:"Angel",middleName:null,surname:"Catala",slug:"angel-catala",fullName:"Angel Catala"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"9606",leadTitle:null,title:"Fatty Liver",subtitle:null,reviewType:"peer-reviewed",abstract:"\r\n\tInterests in Biomarker Research has escalated with relevance to mitochondrial survival and organ disease such as non alcoholic fatty liver disease (NAFLD) in diabetes and Alzheimer’s disease. The global chronic disease epidemic is expected to cost Biomarker Research between 40 to 60 billion dollars in the next 20 years. Biomarkers are now relevant to mitochondrial apoptosis versus mitochondrial biogenesis and may supersede the various biomarkers tests relevant to NAFLD, diabetes and neurodegenerative disease research. Drug therapy and specific diets are essential early in life to prevent and delay liver steatosis that progresses to NAFLD in global communities. Biotherapeutics in health and disease involve genomic medicine that stabilizes liver disease and the progression to NAFLD.
\r\n\r\n\tEarly diagnosis with relevance to various biomarkers is now important to determine the role of drug and nutritional therapy with relevance to the reversal of liver steatosis. Antiaging research with relevance to anti-aging genes are now critical to the global chronic disease epidemic and the prevention of NAFLD that is expected to rise to 30% of the global population by 2050.
",isbn:"978-1-83968-639-9",printIsbn:"978-1-83968-638-2",pdfIsbn:"978-1-83968-640-5",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,hash:"f7fc7c1193ad5fa2b11b74acf6b1137e",bookSignature:"Dr. Ian Martins",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/9606.jpg",keywords:"Antiaging Genes, Non-alcoholic Fatty Liver Disease, Appetite, Reversal, Advances, Diagnostic, Bacterial Contamination, Fatty Liver, Mitochondria, Aging, Inactivation, Metabolism",numberOfDownloads:15,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:0,numberOfTotalCitations:0,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"September 1st 2020",dateEndSecondStepPublish:"September 29th 2020",dateEndThirdStepPublish:"November 28th 2020",dateEndFourthStepPublish:"February 16th 2021",dateEndFifthStepPublish:"April 17th 2021",remainingDaysToSecondStep:"5 months",secondStepPassed:!0,currentStepOfPublishingProcess:5,editedByType:null,kuFlag:!1,biosketch:"World Academic Champion - 2017 in Medical Science (Nutrition), Fellow, Directorate of Medical Science (Nutrition), International Agency for Standards and Ratings. Conferred with the Richard Kuhn Research Award (2015) Endocrinology and Metabolism.",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"179745",title:"Dr.",name:"Ian",middleName:null,surname:"Martins",slug:"ian-martins",fullName:"Ian Martins",profilePictureURL:"https://mts.intechopen.com/storage/users/179745/images/system/179745.jpg",biography:"Dr. Ian James Martins is an Editor/Reveiwer for Open Acess Pub/MDPI journals and various other international journals. Advisory Board Member for Photon Journal. Fellow of International Agency for Standards and Ratings (IASR). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM. Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews: Neuroscience (2016-2018) and Journal of Diabetes and Clinical Studies (2017-2018). BIT Member (BIT Congress. Inc) with an H-index of 64, (ResearchGate STATs (27), Scopus Author ID: 7103152779/Mendeley STATS (21), UWA Research Repository (16). Scientist for The Science Advisory Board (USA) and an Academic with Academia.edu. The citations past 27 years have accumulated to >4584. Ian James Martins - Semantic Scholar https://www.semanticscholar.org/author/Ian-James-Martins/5258067. Semantic Scholar profile for Ian James Martins, with fewer than 50 highly influential citations RESEARCHGATE ANALYSIS: Ian J Martins | Ph D | Centre of Excellence for Alzheimer\\'s Disease ...https://www.researchgate.net/profile/Ian_Martins2 under Ian James Martins’ name places publication RG score (> 96%) of international SCIENTISTS. ORCID CONNECTING RESEARCHER: Editorial Team www.macrothink.org/journal/index.php/jfs/about/editorialTeamBio/13511 Editorial Team. Ian James Martins. Ian James Martins Mail · http://orcid.org/0000-0002-2390-1501. Edith Cowan University, Australia. Prestigious Recognition of Lifetime Membership by International Agency for Standards and Ratings as Fellow for Diabetes, Medical Science (Nutrition). Winner (World Academic Championship -2017) in Diabetes and Medical Science (Nutrition). Certificates from various international conferences have been received in relation to anti-aging, health and disease. Keynote addresses at, Biomedicine 2018 (Osaka, Japan), Global Experts Meeting on Diabetes, Hypertension, Metabolic Syndrome 2018 (Melbourne, Australia), Immunology World 2018 (Amsterdam, Netherlands), Laboratory Medicine 2018 (Berlin, Germany), Innovate Pharma 2017 (Sydney, Australia), Innovate Neurology 2017(Sydney, Australia) World Diabetes and Endocrinology Summit-2017 (Dubai), Pharmacology and Ethnopharmacology 2016 (Chicago, USA) and AGHC 2016 (1st Plenary Speaker, Kaohsiung, Taiwan). Chair/Co-chair Sessions on Laboratory management, Cytogenetics, Clinical Microbiology, Diagnostic Laboratory Medicine etc, 13th Interantional Conference on Laboratory Medicine and Pathology, Berlin, Germany, June 25-26, 2018, Chairing Sessions on Vaccinology, Immunopathology, Immunotherapy, Immune Proteomics, Cancer and Tumour Oncology, 7th World Congress on Immunology, Amsterdam, Netherlands, April 19-20, 2018, Chair, Pipeline 1: Biotherapeutics for Diseases, Bit\\'s 2nd International Congress of Biotherapy-2018 (Programme Committee Member), Chair, Innovate Conferences 2017, Chair/Co-Chair at congress World Gene Convention-2016 (Shanghai, China, Pharmacology and Ethanopharmacology 2016 (Chicago, USA), Annual World Congress of Diabetes-2014 (Haikou, China), World Gene Convention-2014 (Haikou, China). Research Activity Statistics have been provided by Publons with comparison to other researchers. Ian James Martins is now in the 98th percentile as assessed for Publons users by merit. Dr Ian Martins is a reviewer for approx. 47 journals over the past 5 years. \r\n\r\n RESEARCH INTERESTS Anti-Aging, Global Health and Chronic Disease",institutionString:"Edith Cowan University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"2",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Edith Cowan University",institutionURL:null,country:{name:"Australia"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"16",title:"Medicine",slug:"medicine"}],chapters:[{id:"75318",title:"Diagnosis of Nonalcoholic Steatohepatitis",slug:"diagnosis-of-nonalcoholic-steatohepatitis",totalDownloads:15,totalCrossrefCites:0,authors:[null]}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"252211",firstName:"Sara",lastName:"Debeuc",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/252211/images/7239_n.png",email:"sara.d@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"6550",title:"Cohort Studies in Health Sciences",subtitle:null,isOpenForSubmission:!1,hash:"01df5aba4fff1a84b37a2fdafa809660",slug:"cohort-studies-in-health-sciences",bookSignature:"R. Mauricio Barría",coverURL:"https://cdn.intechopen.com/books/images_new/6550.jpg",editedByType:"Edited by",editors:[{id:"88861",title:"Dr.",name:"R. Mauricio",surname:"Barría",slug:"r.-mauricio-barria",fullName:"R. Mauricio Barría"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"878",title:"Phytochemicals",subtitle:"A Global Perspective of Their Role in Nutrition and Health",isOpenForSubmission:!1,hash:"ec77671f63975ef2d16192897deb6835",slug:"phytochemicals-a-global-perspective-of-their-role-in-nutrition-and-health",bookSignature:"Venketeshwer Rao",coverURL:"https://cdn.intechopen.com/books/images_new/878.jpg",editedByType:"Edited by",editors:[{id:"82663",title:"Dr.",name:"Venketeshwer",surname:"Rao",slug:"venketeshwer-rao",fullName:"Venketeshwer Rao"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4816",title:"Face Recognition",subtitle:null,isOpenForSubmission:!1,hash:"146063b5359146b7718ea86bad47c8eb",slug:"face_recognition",bookSignature:"Kresimir Delac and Mislav Grgic",coverURL:"https://cdn.intechopen.com/books/images_new/4816.jpg",editedByType:"Edited by",editors:[{id:"528",title:"Dr.",name:"Kresimir",surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"34271",title:"A Comparison of Non Negative Blind Source Separation Methods for Identifying Astrophysical Ice Compounds",doi:"10.5772/32274",slug:"a-comparison-of-non-negative-blind-source-separation-methods-for-identifying-astrophysical-ice-compo",body:null,keywords:null,chapterPDFUrl:"https://cdn.intechopen.com/pdfs/34271.pdf",chapterXML:null,downloadPdfUrl:"/chapter/pdf-download/34271",previewPdfUrl:"/chapter/pdf-preview/34271",totalDownloads:1773,totalViews:83,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,dateSubmitted:"April 8th 2011",dateReviewed:"November 10th 2011",datePrePublished:null,datePublished:"March 30th 2012",dateFinished:null,readingETA:"0",abstract:null,reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/34271",risUrl:"/chapter/ris/34271",book:{slug:"astrophysics"},signatures:"Jorge Igual and Raul llinares",authors:[{id:"2290",title:"Dr.",name:"Raul",middleName:null,surname:"Llinares",fullName:"Raul Llinares",slug:"raul-llinares",email:"rllinares@dcom.upv.es",position:null,institution:{name:"Universitat Politècnica de València",institutionURL:null,country:{name:"Spain"}}},{id:"90804",title:"Dr.",name:"Jorge",middleName:null,surname:"Igual",fullName:"Jorge Igual",slug:"jorge-igual",email:"jigual@dcom.upv.es",position:null,institution:{name:"Universitat Politècnica de València",institutionURL:null,country:{name:"Spain"}}}],sections:null,chapterReferences:null,footnotes:null,contributors:null,corrections:null},book:{id:"1629",title:"Astrophysics",subtitle:null,fullTitle:"Astrophysics",slug:"astrophysics",publishedDate:"March 30th 2012",bookSignature:"Ibrahim Kucuk",coverURL:"https://cdn.intechopen.com/books/images_new/1629.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"102957",title:"Prof.",name:"İbrahim",middleName:null,surname:"Küçük",slug:"ibrahim-kucuk",fullName:"İbrahim Küçük"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"34257",title:"Nuclear Excitation Processes in Astrophysical Plasmas",slug:"nuclear-excitation-processes-in-astrophysical-plasmas",totalDownloads:2020,totalCrossrefCites:0,signatures:"G. Gosselin, P. Mohr, V. Méot and P. Morel",authors:[{id:"109302",title:"Mr.",name:"Gilbert",middleName:null,surname:"Gosselin",fullName:"Gilbert Gosselin",slug:"gilbert-gosselin"},{id:"109409",title:"Dr.",name:"Vincent",middleName:null,surname:"Meot",fullName:"Vincent Meot",slug:"vincent-meot"},{id:"109410",title:"Dr.",name:"Pascal",middleName:null,surname:"Morel",fullName:"Pascal Morel",slug:"pascal-morel"},{id:"112136",title:"Dr.",name:"Peter",middleName:null,surname:"Mohr",fullName:"Peter Mohr",slug:"peter-mohr"}]},{id:"34258",title:"Stellar Nucleosynthesis Nuclear Data Mining",slug:"stellar-nucleosynthesis-nuclear-data-mining",totalDownloads:2560,totalCrossrefCites:0,signatures:"Boris Pritychenko",authors:[{id:"100207",title:"Dr.",name:"Boris",middleName:null,surname:"Pritychenko",fullName:"Boris Pritychenko",slug:"boris-pritychenko"}]},{id:"34259",title:"The s-Process Nucleosynthesis in Massive Stars: Current Status and Uncertainties due to Convective Overshooting",slug:"the-s-process-nucleosynthesis-in-massive-stars-current-status-and-uncertainties-due-to-convective-ov",totalDownloads:2072,totalCrossrefCites:0,signatures:"M. L. Pumo",authors:[{id:"99589",title:"Dr.",name:"Maria Letizia",middleName:null,surname:"Pumo",fullName:"Maria Letizia Pumo",slug:"maria-letizia-pumo"}]},{id:"34260",title:"The r-Process of Nucleosynthesis: The Puzzle Is Still with Us",slug:"the-r-process-of-nucleosynthesis-the-puzzle-is-still-with-us",totalDownloads:1859,totalCrossrefCites:0,signatures:"Marcel Arnould and Stephane Goriely",authors:[{id:"108278",title:"Prof.",name:"Marcel",middleName:null,surname:"Arnould",fullName:"Marcel Arnould",slug:"marcel-arnould"},{id:"108283",title:"Dr.",name:"Stephane",middleName:null,surname:"Goriely",fullName:"Stephane Goriely",slug:"stephane-goriely"}]},{id:"34261",title:"Diffuse Emission of 26Al and 60Fe in the Galaxy",slug:"diffuse-emission-of-26al-and-60fe-in-the-galaxy",totalDownloads:1790,totalCrossrefCites:0,signatures:"Wei Wang",authors:[{id:"104833",title:"Dr.",name:"Wei",middleName:null,surname:"Wang",fullName:"Wei Wang",slug:"wei-wang"}]},{id:"34262",title:"Energy Generation Mechanisms in Stellar Interiors",slug:"energy-generation-mechanisms-in-stellar-interiors",totalDownloads:1955,totalCrossrefCites:0,signatures:"İbrahim Küçük",authors:[{id:"102957",title:"Prof.",name:"İbrahim",middleName:null,surname:"Küçük",fullName:"İbrahim Küçük",slug:"ibrahim-kucuk"}]},{id:"34263",title:"The Lane-Emden-Fowler Equation and Its Generalizations - Lie Symmetry Analysis",slug:"the-lane-emden-equation-and-its-generalizations",totalDownloads:3492,totalCrossrefCites:1,signatures:"Chaudry Masood Khalique",authors:[{id:"94177",title:"Dr.",name:"Chaudry",middleName:"Masood",surname:"Khalique",fullName:"Chaudry Khalique",slug:"chaudry-khalique"}]},{id:"34264",title:"The Missing Matter Problem: From the Dark Matter Search to Alternative Hypotheses",slug:"the-missing-matter-problem-from-dark-matter-to-alternative-hypotheses",totalDownloads:1632,totalCrossrefCites:1,signatures:"S. Capozziello, L. Consiglio, M. De Laurentis, G. De Rosa and C. Di Donato",authors:[{id:"92637",title:"Dr.",name:"Gianfranca",middleName:null,surname:"De Rosa",fullName:"Gianfranca De Rosa",slug:"gianfranca-de-rosa"},{id:"101532",title:"Prof.",name:"Salvatore",middleName:null,surname:"Capozziello",fullName:"Salvatore Capozziello",slug:"salvatore-capozziello"},{id:"101536",title:"Dr.",name:"Camilla",middleName:null,surname:"Di Donato",fullName:"Camilla Di Donato",slug:"camilla-di-donato"},{id:"101541",title:"Dr.",name:"Mariafelicia",middleName:null,surname:"De Laurentis",fullName:"Mariafelicia De Laurentis",slug:"mariafelicia-de-laurentis"},{id:"101542",title:"Dr.",name:"Lucia",middleName:null,surname:"Consiglio",fullName:"Lucia Consiglio",slug:"lucia-consiglio"}]},{id:"34265",title:"A Microscopic Equation of State for Neutron-Rich Matter and Its Effect on Neutron Star Properties",slug:"neutron-star-properties-and-the-nuclear-equation-of-state",totalDownloads:1449,totalCrossrefCites:0,signatures:"Francesca Sammarruca",authors:[{id:"89963",title:"Prof.",name:"Francesca",middleName:null,surname:"Sammarruca",fullName:"Francesca Sammarruca",slug:"francesca-sammarruca"}]},{id:"34266",title:"Methods for Image Recognition of Charged Particle Tracks in Track Detector Data Automated Processing",slug:"methods-for-image-recognition-of-charged-particle-tracks-in-track-detector-data-automated-processing",totalDownloads:8056,totalCrossrefCites:0,signatures:"A.B. Aleksandrov, N.G. Polukhina and N.I. Starkov",authors:[{id:"90408",title:"Prof.",name:"Natalia",middleName:null,surname:"Polukhina",fullName:"Natalia Polukhina",slug:"natalia-polukhina"},{id:"100258",title:"Prof.",name:"Nikolai",middleName:null,surname:"Starkov",fullName:"Nikolai Starkov",slug:"nikolai-starkov"},{id:"100259",title:"Dr.",name:"Andrey",middleName:null,surname:"Aleksandrov",fullName:"Andrey Aleksandrov",slug:"andrey-aleksandrov"}]},{id:"34267",title:"Implementation of Dynamic Logic Algorithm for Detection of EM Fields Scattered by Langmuir Soliton",slug:"implementation-of-dynamic-logic-algorithm-for-detection-of-em-fields-scattered-by-langmuir-soliton",totalDownloads:1416,totalCrossrefCites:0,signatures:"V.I. Sotnikov, R.W. Deming and L. Perlovsky",authors:[{id:"97711",title:"Dr",name:null,middleName:null,surname:"Sotnikov",fullName:"Sotnikov",slug:"sotnikov"}]},{id:"34268",title:"Visualization Methods for Numerical Astrophysics",slug:"visualization-methods-for-numerical-astrophysics",totalDownloads:1957,totalCrossrefCites:1,signatures:"Werner Benger, Markus Haider, Harald Höller, Dominik Steinhauser, Josef Stöckl, Biagio Cosenza and Marcel Ritter",authors:[{id:"90557",title:"Dr.",name:"Werner",middleName:null,surname:"Benger",fullName:"Werner Benger",slug:"werner-benger"},{id:"112252",title:"MSc.",name:"Markus",middleName:null,surname:"Haider",fullName:"Markus Haider",slug:"markus-haider"},{id:"112253",title:"Dr.",name:"Josef",middleName:null,surname:"Stoeckl",fullName:"Josef Stoeckl",slug:"josef-stoeckl"},{id:"112254",title:"Dr.",name:"Biagio",middleName:null,surname:"Cosenza",fullName:"Biagio Cosenza",slug:"biagio-cosenza"},{id:"112257",title:"MSc.",name:"Marcel",middleName:null,surname:"Ritter",fullName:"Marcel Ritter",slug:"marcel-ritter"},{id:"112258",title:"MSc.",name:"Dominik",middleName:null,surname:"Steinhauser",fullName:"Dominik Steinhauser",slug:"dominik-steinhauser"},{id:"128849",title:"MSc.",name:"Harald",middleName:null,surname:"Hoeller",fullName:"Harald Hoeller",slug:"harald-hoeller"}]},{id:"34269",title:"Asteroseismology of Vibration Powered Neutron Stars",slug:"asteroseismology-of-vibration-powered-neutron-stars",totalDownloads:2134,totalCrossrefCites:0,signatures:"Sergey Bastrukov, Renxin Xu, Junwei Yu, Irina Molodtsova and Hsiang-Kuang Chang",authors:[{id:"92999",title:"Dr.",name:"Sergey",middleName:null,surname:"Bastrukov",fullName:"Sergey Bastrukov",slug:"sergey-bastrukov"},{id:"93004",title:"Dr.",name:"Irina",middleName:null,surname:"Molodtsova",fullName:"Irina Molodtsova",slug:"irina-molodtsova"},{id:"94322",title:"MSc.",name:"Junwei",middleName:null,surname:"Yu",fullName:"Junwei Yu",slug:"junwei-yu"},{id:"94323",title:"Prof.",name:"Renxin",middleName:null,surname:"Xu",fullName:"Renxin Xu",slug:"renxin-xu"},{id:"106311",title:"Prof.",name:"Hsiang-Kuang",middleName:null,surname:"Chang",fullName:"Hsiang-Kuang Chang",slug:"hsiang-kuang-chang"}]},{id:"34270",title:"Energetic Charged Particles in the Heliosphere from 1-120 AU Measured by the Voyager Spacecraft",slug:"charged-particle-intensities-in-the-heliosphere-as-measured-by-voyagers-1-and-2",totalDownloads:1364,totalCrossrefCites:0,signatures:"W.R. Webber",authors:[{id:"114311",title:"Prof.",name:"William R",middleName:null,surname:"Webber",fullName:"William R Webber",slug:"william-r-webber"}]},{id:"34271",title:"A Comparison of Non Negative Blind Source Separation Methods for Identifying Astrophysical Ice Compounds",slug:"a-comparison-of-non-negative-blind-source-separation-methods-for-identifying-astrophysical-ice-compo",totalDownloads:1773,totalCrossrefCites:0,signatures:"Jorge Igual and Raul llinares",authors:[{id:"2290",title:"Dr.",name:"Raul",middleName:null,surname:"Llinares",fullName:"Raul Llinares",slug:"raul-llinares"},{id:"90804",title:"Dr.",name:"Jorge",middleName:null,surname:"Igual",fullName:"Jorge Igual",slug:"jorge-igual"}]},{id:"34272",title:"Graviton Emission in the Bulk and Nucleosynthesis in a Model with Extra Dimension",slug:"graviton-emission-in-the-bulk-and-nucleosynthesis-in-a-model-with-extra-dimension-",totalDownloads:1281,totalCrossrefCites:0,signatures:"Mikhail Z. Iofa",authors:[{id:"100559",title:"Dr.",name:"Iofa",middleName:null,surname:"Mikhail",fullName:"Iofa Mikhail",slug:"iofa-mikhail"}]},{id:"34273",title:"Putting Einstein to Test - Astrometric Experiments from Space, Fundamental Physics and Local Cosmology",slug:"putting-einstein-to-test-astrometric-experiments-from-space-fundamental-physics-and-local-cosmology",totalDownloads:1631,totalCrossrefCites:0,signatures:"Alberto Vecchiato",authors:[{id:"97352",title:"Dr.",name:"Alberto",middleName:null,surname:"Vecchiato",fullName:"Alberto Vecchiato",slug:"alberto-vecchiato"}]},{id:"34274",title:"BBN as Probe of Fundamental Physics",slug:"bbn-as-probe-of-fundamental-physics",totalDownloads:1755,totalCrossrefCites:0,signatures:"L. A. Popa and A. Caramete",authors:[{id:"99744",title:"Prof.",name:"Lucia",middleName:null,surname:"Popa",fullName:"Lucia Popa",slug:"lucia-popa"},{id:"152277",title:"Dr.",name:"Ana",middleName:null,surname:"Caramete",fullName:"Ana Caramete",slug:"ana-caramete"}]}]},relatedBooks:[{type:"book",id:"8444",title:"Lunar Science",subtitle:null,isOpenForSubmission:!1,hash:"f1dcf511a174e8ec89d97ca8c0c6146a",slug:"lunar-science",bookSignature:"Yann H. Chemin",coverURL:"https://cdn.intechopen.com/books/images_new/8444.jpg",editedByType:"Edited by",editors:[{id:"270578",title:"Dr.",name:"Yann",surname:"Chemin",slug:"yann-chemin",fullName:"Yann Chemin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"67064",title:"Introductory Chapter: A Tipping Point for a Return to the Moon",slug:"introductory-chapter-a-tipping-point-for-a-return-to-the-moon",signatures:"Yann H. Chemin",authors:[{id:"270578",title:"Dr.",name:"Yann",middleName:"H.",surname:"Chemin",fullName:"Yann Chemin",slug:"yann-chemin"}]},{id:"65612",title:"Initial Evolution of the Moon",slug:"initial-evolution-of-the-moon",signatures:"Khachay Yuriy",authors:[{id:"225379",title:"Prof.",name:"Yuriy",middleName:null,surname:"Khachay",fullName:"Yuriy Khachay",slug:"yuriy-khachay"}]},{id:"65725",title:"On the Deviation of the Lunar Center of Mass to the East: Two Possible Mechanisms Based on Evolution of the Orbit and Rounding Off the Shape of the Moon",slug:"on-the-deviation-of-the-lunar-center-of-mass-to-the-east-two-possible-mechanisms-based-on-evolution-",signatures:"Boris P. Kondratyev",authors:[{id:"277909",title:"Prof.",name:"Boris",middleName:"Petrovich",surname:"Kondratyev",fullName:"Boris Kondratyev",slug:"boris-kondratyev"}]},{id:"65508",title:"New Principles of Monitoring Seismological and Deformation Processes Occurring in the Moon Rock Massive",slug:"new-principles-of-monitoring-seismological-and-deformation-processes-occurring-in-the-moon-rock-mass",signatures:"Olga Hachay and Oleg Khachay",authors:[{id:"150801",title:"Prof.",name:"Olga",middleName:"Alexandrovna",surname:"Hachay",fullName:"Olga Hachay",slug:"olga-hachay"},{id:"263300",title:"Dr.",name:"Oleg",middleName:null,surname:"Khachay",fullName:"Oleg Khachay",slug:"oleg-khachay"}]},{id:"66992",title:"Lunar Occultation",slug:"lunar-occultation",signatures:"Abdulrahman Malawi",authors:[{id:"282963",title:"Dr.",name:"Abdulrahman",middleName:"Ali",surname:"Malawi",fullName:"Abdulrahman Malawi",slug:"abdulrahman-malawi"}]},{id:"65534",title:"Solar System Exploration Augmented by In Situ Resource Utilization: Lunar Base Issues",slug:"solar-system-exploration-augmented-by-in-situ-resource-utilization-lunar-base-issues",signatures:"Bryan Palaszewski",authors:[{id:"279275",title:"M.Sc.",name:"Bryan",middleName:null,surname:"Palaszewski",fullName:"Bryan Palaszewski",slug:"bryan-palaszewski"}]},{id:"65461",title:"Human Health in the Lunar Environment",slug:"human-health-in-the-lunar-environment",signatures:"Robert J. Reynolds",authors:[{id:"220737",title:"Dr.",name:"Robert",middleName:null,surname:"J. Reynolds",fullName:"Robert J. Reynolds",slug:"robert-j.-reynolds"}]}]}]},onlineFirst:{chapter:{type:"chapter",id:"67248",title:"Update on Mechanisms, Pathogenicity, Heterogeneity of Presentation, and Laboratory Diagnosis of Heparin-Induced Thrombocytopenia",doi:"10.5772/intechopen.86475",slug:"update-on-mechanisms-pathogenicity-heterogeneity-of-presentation-and-laboratory-diagnosis-of-heparin",body:'The major adverse effect of heparin therapy concerns probably the development of thrombocytopenia and thromboembolic complications, which are directly caused by the drug itself [1, 2, 3, 4, 5, 6]. This heparin paradox is associated with a characteristic platelet fall and thrombosis in some heparin-treated patients, especially when unfractionated heparin (UFH) is used, but it can also occur with low molecular weight heparin (LMWH) therapy. The patient’s clinical context can favor the development of this iatrogenic complication, called heparin-induced thrombocytopenia (HIT) without or with associated thrombosis (HITT). When this complication occurs, it requires an immediate management with the withdrawal of heparin and use of an alternative anticoagulant [7, 8, 9, 10, 11]. If incorrectly managed, it can rapidly cause severe burden and become life-threatening. This complication is reported to occur in about 1–5% of patients treated with UFH and 0.2–0.5% of those treated with LMWH, but the incidence highly depends on the clinical context [1, 3, 5, 6]. Cardiology or orthopedic surgery, trauma, circulatory diseases, and the presence of tumors are increased risk factors for that disease. A recent meta-analysis in the USA reported a different HIT/HITT incidence and clinical association than that usually accepted but shows that it remains a critical clinical issue in hospitals [5]. The first alert signal for HIT is a platelet count drop by more than 30–50% between two successive measures, occurring between 5 and 15 days following the onset of heparin therapy, in the absence of any other thrombocytopenia cause (Table 1). However, platelet fall can develop earlier if patients have been exposed to heparin during the 3 months preceding the treatment. The mechanisms producing HIT involve the generation of a heparin-dependent antibody, usually of the IgG isotype (but IgA and IgM isotypes can also be present). This antibody has been demonstrated to be targeted to complexes of heparin and platelet factor 4 (PF4) in most of the cases [12, 13], but non-PF4 antigens can be present in some atypical patients [14, 15, 16, 17]. Frequently, heparin-dependent antibodies, including IgG isotypes, are asymptomatic [18, 19]. They are symptomatic and harmful only in a few subsets of affected patients. What renders the antibodies pathogenic in those patients is not totally understood, but some evidence becomes available. IgG isotypes present at high concentration, and with high avidity, provoke frequently the development of disease [19, 20]. Clinical diagnosis and laboratory diagnosis are of high importance to rapidly identify the patients with an active disease and treat them [6, 8, 21, 22, 23, 24]. It includes a multiple strategy approach:
early detection of patients with thrombocytopenia
evaluation of their HIT clinical score
testing for the presence of heparin-dependent antibodies with immunoassays
checking the capability of these antibodies to activate platelets in a heparin-dependent mode [25].
|
Risk factors for HIT development during heparin therapy.
It is of essence to duly characterize patients with HIT: if this complication is excluded, it is not necessary to deprive them from heparin, as it is the most effective anticoagulant in many acute conditions. Conversely, if HIT/HITT is confirmed, it is mandatory to not reintroduce any heparin treatment and to switch to an alternative anticoagulation. In this book chapter, we will present and discuss the following: (a) the present understandings of conditions which can favor development of heparin-dependent antibodies in heparin-treated patients; (b) why antibodies generate HIT or HITT only in a few subset of patients; (c) the mechanisms of action of these antibodies, as they are presently understood; (d) the available laboratory tools and their indications; (e) the diagnostic strategy for rapidly characterizing patients at risk; (f) the occurrence of atypical presentations of HIT in patients with pre-existing antibodies to PF4 or to interleukin 8 (IL8) or with antibodies to protamine sulfate (PrS); and (g) cross-reactivity of the various polysaccharide anticoagulants in immunoassays and functional methods. This chapter mainly focuses on antibodies generated to heparin-PF4 (HPF4) complexes, which concern most of the patients with HIT/HITT, but other non-PF4 antigens can be involved in few cases and will be rapidly discussed.
Heparin-dependent antibodies develop in many patients treated with UFH or LMWH. Their incidence is higher in patients undergoing extracorporeal circulation (ECC) for cardiopulmonary bypass (CPB) or extracorporeal membrane oxygenation (ECMO) [5, 26, 27]. Antibodies’ development is not rare during heparin therapy, but they are often of the IgM isotype with a rapid reversal without any clinical incidence [18, 19]. They can also be of the IgA or IgG isotypes, and the three isotypes are associated in many patients and are frequently asymptomatic. IgGs have been demonstrated to be those which can become pathogenic, especially when present at high concentration, with high affinity for their target heparin-dependent antigen [19, 25]. A subset of the IgG isotype heparin-dependent antibodies can then activate platelets [20], which induce thrombocytopenia, platelet aggregation, and sometimes thrombosis. HIT was first characterized for the white thrombus formed in arteries (platelets and white blood cells), when patients with this complication were first identified, but there is evidence now that arterial (about 30% of cases) or venous (about 70% of cases) thrombosis can occur [28]. Skin necrosis at the injection site or elsewhere, or thrombosis, frequently at limb extremities, is often observed, but thrombosis can occur at many different sites.
In addition to platelet activation, heparin-dependent antibodies can induce activation of endothelial cells (ECs) and of monocytes, and they can release tissue factor (TF) from these cells, which contribute to thrombosis [29, 30, 31]. Platelet-leukocyte aggregates are also formed and contribute to thrombogenicity. When this multiple blood activation process is initiated, it is enhanced at pathological sites where platelet and white blood cells can be chemo-attracted and accumulate with a high density. If blood activation and prothrombotic process are strong enough to overwhelm the antithrombotic body’s defenses, thrombus formation occurs. The first clinical warning for HIT is the occurrence of thrombocytopenia, with a characteristic time kinetics from the onset of therapy, when other causes of decreased platelet counts are excluded [6, 25, 28]. Platelet fall typically occurs between 5 and 15 days following the initiation of treatment, as shown in Figure 1, except if patients already received heparin within the 100 preceding days or in the rare cases with pre-existing anti-PF4 antibodies. Thrombocytopenia can then develop earlier and possibly just at the onset of heparin therapy. In HIT/HITT thrombocytopenia is usually moderate, between 20 and 100 giga platelets per liter (G/L), and it is rarely very severe (<10 G/L). When it develops, the clinical probability for HIT/HITT must be evaluated. It is an important criterion for estimating the risk to develop this complication in heparin-treated patients, and various pretest methods for estimating disease risk are available. The most frequently used is the 4Ts score [28], which considers four major criteria: the presence of thrombocytopenia, the timing of platelet count fall, the occurrence of new thrombosis or sequelae, and the investigation of other causes of thrombocytopenia. For each criterion, a score from 0 to 2 is given, as shown in Table 2. It allows to classify patients from 0 to 8 (risk is low for 0–3, intermediate for 4–5, and high for ≥6, indicating an elevated disease probability). In cardiology patients with ECC, thrombocytopenia is frequently observed, and HIT can be identified when a biphasic platelet count kinetics is present: in the absence of HIT, thrombocytopenia is progressively corrected, but, if present, platelet count starts to increase and falls again when symptomatic antibodies develop [27].
Typical platelet count kinetics in heparin-treated patients who develop heparin-dependent antibodies responsible for heparin-induced thrombocytopenia.
The pretest probability for HIT based on the 4Ts score.
Other HIT clinical evaluation approaches have been proposed (such as the expert score), but the 4Ts score remains the most widely used. When HIT is suspected, heparin treatment must be stopped and replaced by another anticoagulant. The possible drugs which can be used include argatroban, direct oral anticoagulants (DOACs), danaparoid sodium, fondaparinux, and bivalirudin [7, 9, 10, 11, 32, 33]. Nevertheless, if HIT is excluded, heparin can be reintroduced, as it can be of full benefit for the patient, especially in cardiac surgery and circulatory diseases. Establishing rapidly a safe and reliable diagnosis of HIT is then of essence for the right management of patients [6, 25, 28].
HIT/HITT occurs in some of the patients who develop heparin-dependent antibodies, a major risk factor for the disease occurrence. In most of the cases, they are targeted to stoichiometric complexes of heparin and PF4 (HPF4) and are of the IgG isotype but are the only ones present in few patients with atypical HIT/HITT antibodies to IL8 or to PrS [12, 14, 15, 17]. In rare cases, the antibody specificity remains non-identified, although patients present the suggestive clinical complication of heparin therapy. What causes the heparin-dependent antibodies’ generation is not yet fully understood, but drug immunogenicity tends to develop when heparin forms complexes with its high-affinity binding blood protein, PF4, a chemokine from the CXC family [34, 35, 36], and eventually IL8 [37, 38]. In healthy individuals, PF4 is normally present at very low concentrations in blood circulation (<10 ng/ml). It is released from platelets’ α-granules upon activation or aggregation, as a complex of eight PF4 tetramers with a platelet proteoglycan dimer, with a molecular weight (MW) of about 350 kDa. This complex is rapidly cleared from circulation as PF4 is captured by endothelial cells’ glycosaminoglycans (GAGs) and remains in this endothelial storage pool. In patients with inflammation or blood activation, PF4 concentrations can be much higher, either in blood circulation or on the endothelial storage pool. In addition, at pathological sites, platelets and white blood cells can be chemo-attracted and stimulated. Much higher PF4 concentrations can be present at these sites. At the onset of heparin therapy, PF4, which has a higher affinity for this drug than for GAGs or physiological proteoglycans, forms complexes with it, as presented in Figure 2. In some circumstances these complexes can activate the immune system and induce the generation of antibodies. The immune response can be innate, mediated via the toll-like receptors, and adaptive with a T cell-mediated response, followed by the generation of antibodies. The three isotypes (IgG, IgA, or IgM) can be present [13, 19], but IgGs are formed very rapidly, which is unusual in the early stage of the immune response, and IgGs can become rapidly pathogenic [19]. In rare cases, only IgA (especially in patients with cancer) or IgM isotypes are identified [39]. Following heparin treatment cessation, antibodies disappear from blood circulation within about 3 months. The respective concentrations of PF4 and heparin in blood circulation or at pathological sites are key factors for inducing immunogenicity [40, 41]. The clinical context is then a risk factor for heparin-dependent antibodies’ development. Another initial cause which can favor generation of antibodies has been described and concerns a previous exposure of patients to bacterial infections [42]. PF4 can complex with bacterial polysaccharides and then becomes immunogenic. The immune response induces generation of antibodies to this chemokine. When patients with this former stimulation receive heparin, PF4 released from endothelium forms HPF4 complexes which reactivate the immune system (Figure 1), and IgG isotypes are rapidly generated. In addition to PF4, heparin treatment (and more especially LMWH) can also release tissue factor pathway inhibitor (TFPI) bound to ECs into blood circulation. No immune reaction to TFPI has been observed until now, but its increased concentration contributes to elevate the anticoagulant activity of heparin at the beginning of treatment.
At the onset of heparin therapy, TFPI and PF4 “storage pool” are displaced from endothelial cells and released into blood circulation. Heparin complexes with PF4, and this can stimulate the immune system (especially if heparin and PF4 stoichiometric concentrations are met), and antibodies to these complexes are generated.
The major heparin-dependent antigen involved in HIT/HITT is PF4, a CXC chemokine present in platelet α-granules and released upon platelet activation and aggregation. PF4 is a 70 amino acid (AA) protein with a MW of 7800 kDa, released in blood circulation as a tetramer with a MW of about 30 kDa [34, 35, 36, 43]. This chemokine has a structure involving one α-helix and three β-sheets organized in an antiparallel manner; it is highly electropositive, with many lysine and arginine residues, and has two disulfide bridges per monomer. The tetramer is organized in such a way that it exposes an external ring of positive charges, as shown in Figure 3. The formation of HPF4 complexes depends on the respective concentrations of heparin and PF4 [13, 24, 44]. Stoichiometric complexes are formed at a concentration of about 150 μg of heparin (i.e., about 27 IU UFH) per mg of PF4 (Figure 4). High- and low-affinity heparin molecules have the same reactivity with PF4, as well as LMWH, and the sulfation grade is of essence for these interactions. Patients who develop antibodies are those with the highest extracellular concentrations of PF4 in blood circulation, or at pathological sites, and with heparin concentrations permitting the formation of stoichiometric HPF4 complexes.
Reaction of heparin with PF4 tetramers at stoichiometric concentrations. There is an intimate interaction between the ring of positive charges on the PF4 tetramer and the negative charges of the sulfated polysaccharide, heparin. This strong interaction induces an alteration of PF4 structure, rendering it immunogenic. Heparin (UFH or LMWH) molecules with at least 12 monosaccharides are required for this interaction.
PF4 is released from platelets as a complex with a proteoglycan dimer and is displaced by heparin for which it has a higher affinity. Complexes of heparin and PF4 depend on their respective ratios. When heparin and PF4 are at a stoichiometric concentration, large multimolecular complexes are formed and can be exposed on platelets or other blood cells. They can bind heparin-dependent antibodies and focus the deleterious immune reaction onto these cells. This can induce HIT or HITT in some patients.
If heparin treatment is given through continuous infusion, heparin concentration remains constant in blood circulation, and the risk to form stoichiometric HPF4 reactive complexes is reduced. When heparin is given through the subcutaneous route, blood concentrations present high variations, from <0.1 IU/ml at trough to >0.7 IU/ml at peak. For current curative UFH treatments (2–3 injections/day), the PF4 concentrations needed for forming stoichiometric complexes must be of about 4 μg/ml for heparin concentrations ≤0.1 IU/ml (trough) or of ≥28 μg/ml for heparin concentrations ≥0.7 IU/ml (peak). Required PF4 concentrations are high comparatively to expected heparin concentrations in blood circulation, even in disease states, but these high concentrations could be present at pathological sites. In ECC, blood heparin concentrations are high (about 4–5 IU/ml) and constant: formation of stoichiometric complexes can only occur with 25–30 μg/ml of PF4, which is unlikely. For information, the total amount of PF4 releasable from platelets, when they are totally activated and aggregated, is of about 5 μg per ml of blood (depending on platelet count and PF4 content; it is of ±12.5 ng/106 platelets).
But PF4 can accumulate and be at higher concentrations at pathological sites. Immunogenic stimulation occurs when body detects a non-self-component, which can be heparin used as anticoagulant. When bound to PF4, it forms large complexes, which can activate the immune response, which is targeted to these complexes and possibly extended to PF4 itself, through epitope spreading. Generated antibodies can be considered as alloantibodies. In few cases, PF4 antibodies can be pre-existing chronically or generated transitory as a side response to an infectious disease [14, 42, 45]. Anti-PF4 autoantibodies can bind to HPF4 complexes formed during heparin therapy and are then targeted to platelets or other blood cells which expose HPF4 complexes, focusing the deleterious immune response [22, 29, 30, 46]. In few cases, non-PF4 antigens can be involved [14, 15, 17, 46, 47]. HIT/HITT presentation and disease kinetics are then frequently atypical, although a moderate or characteristic thrombocytopenia develops during heparin therapy. IL8 has been reported in some patients as another heparin-dependent antigen in HIT/HITT. Anti-IL8 antibodies are pre-existing in many patients with chronic inflammation and are generated as a regulatory response to control this pathological context. Pathogenicity can occur because IL8 can bind heparin, and these complexes are fixed onto platelets and other blood cells through IL8 receptors (IL8-RA and IL8-RB) or through direct heparin binding [37, 38]. Interestingly, heparin binding to platelets increases with their activation grade. Anti-IL8 antibodies then focus the immune response deleterious effects to blood cells exposing heparin IL8 complexes which are then activated or destroyed. Neutrophil-activating peptide 2 (NAP-2), the β-thromboglobulin precursor, is another platelet CXC chemokine reported as a possible heparin-dependent antigen in rare HIT cases [14]. Lastly, in patients undergoing ECC [16, 26, 27], heparin is used as anticoagulant and is neutralized with a defined concentration of PrS at the end of the process. Anti-PrS or anti-heparin-PrS antibodies have been the only ones identified in few patients treated with heparin and presenting with a HIT-/HITT-like syndrome [17], with a possible fatal outcome. These antibodies can activate platelets in the presence of heparin [15, 46, 47]. Recent investigations have shown that anti-PrS antibodies are rather frequent in patients receiving this drug for heparin neutralization, but only very few of them develop severe clinical complications. Recurrent ECC in the same patient, with various exposures to heparin and PrS over time, can be an increased risk for development of antibodies and associated pathogenicity, with a HIT-/HITT-like syndrome.
Heparin-dependent antibodies, and especially those to HPF4 complexes, induce thrombocytopenia and thrombosis in some clinical circumstances [46]. Particularly IgG isotypes can activate platelets, ECs, or other white blood cells such as monocytes, when they bind to their target antigenic structure, present at the surface of these cells [28, 29, 44, 46, 47]. There is now evidence that heparin and HPF4 complexes bind to platelets’ surface, and this binding increases with their activation grade. HPF4 complexes fix antibodies and target the immune response, provoking platelet activation, aggregation, and interaction with other blood cells. During the process, IgGs react with platelet CD32, which is the FcɣRIIa receptor [44, 46]. This contributes to amplify platelet activation and aggregation. The CD32 surface density is an important factor for the amplitude of platelet activation induced by antibodies. In patients with platelets presenting a CD32 polymorphism (131 Arg-His), activation is enhanced: the 131-Arg-His heterozygous or 131-His-His homozygous CD32 phenotypes are more reactive than the 131-Arg-Arg one. The patient propensity to develop HIT or HITT can depend on platelet activation grade and density or polymorphism of CD32. Antibodies to HPF4 can activate ECs and monocytes, favoring the release of TF, a potent procoagulant starter [29, 30]. In patients with HIT/HITT, neutrophils are activated and form aggregates with platelets, which can be detected in blood circulation. Therefore, the presence of anti-HPF4 IgG antibodies initiates multiple abnormal activities in blood circulation, which induce platelet activation and destruction and a concomitant prothrombotic risk (Figure 5). Blood activation can be out of control from body’s antithrombotic defenses, which are overwhelmed, and thrombosis occurs. Interestingly, thrombosis tends to occur at pre-existing pathological sites, where blood activation and inflammation are already activated, and the risk is greatly amplified by anti-HPF4 antibodies, as summarized in Figure 4. We have the experience that an additional factor is very important for the initiation and amplification of the pathological process. This concerns the antibody avidity for HPF4 complexes [20]. In three patients with HIT or HITT, we succeeded to separate anti-HPF4 IgGs into two groups: the most important (>90%) one had a low affinity for HPF4 and no or only a weak platelet activation capacity, while the minor one (≤10%) activated highly platelets, as evidenced with the C14-serotonin release assay. In few cases, only IgA isotypes specific for HPF4 complexes were identified in patients with HITT and malignant diseases. Although rare, IgAs can be pathogenic in some autoimmune disorders [49, 50], and this is not unexpected to note their effect in HIT. More rarely, IgM can be present at high concentration in patients with HIT, without IgGs. The mechanisms involved are not totally understood, but recently it was demonstrated that anti-HPF4 IgM antibodies can activate complement and induce platelet destruction [39]. Altogether, the different activities described here above help to understand why HPF4 antibodies, including IgG isotypes, can remain asymptomatic in many patients and produce (especially IgG isotypes with high HPF4 affinity) HIT or HITT only in a few of them. The pathogenic process is multifactorial and involves activation and interaction of various blood cells, with the prothrombotic activity of TF. Patients’ pathophysiological history and clinical status provide additional risk factors for the occurrence of disease [5, 6].
Scheme showing how heparin-dependent antibodies, targeted to HPF4 complexes, bind to platelets and endothelial cells but also to monocytes and induce platelet and EC activation, monocyte stimulation, release of TF, and formation of aggregates, all contributing to thrombocytopenia and thrombosis.
Nevertheless, there is still a fortuity context for the occurrence of the HIT/HITT complication, which relies on the formation of the immunoreactive HPF4 complexes, requiring defined concentrations of PF4 and heparin, exposed on blood cells [48]. This is a pre-requisite condition for permitting the binding of antibodies and starting the pathogenic process. This explains why this disease develops so rapidly when the critical conditions are met.
Many different assays are available for the diagnosis of heparin-dependent antibodies and for testing their capability to activate platelets. They are classified into two groups: immunoassays [23, 25, 51, 52], developed following the discovery of PF4 as the major target heparin-dependent antigen, and functional assays, performed with a low and a high heparin concentration, which were already used before [53]. A murine monoclonal antibody (KKO) has been developed and mimics HIT-associated antibodies, with platelet activation capability [54]. Here below we discuss the laboratory methods, and their combination, for the diagnosis of HIT/HITT. Diagnosis combines the clinical probability pretest with laboratory investigations [25]. For laboratory testing, the specimen used is plasma or serum for immunoassays and citrated plasma or heat-inactivated serum for functional assays. These techniques provide a laboratory support to establish, confirm, or exclude the diagnosis of HIT/HITT and must always be used in association with the pretest clinical probability. When HIT is suspected with a characteristic thrombocytopenia, heparin must be discontinued and replaced with another anticoagulant.
With the discovery of the major target antigen for heparin-dependent antibodies, i.e., HPF4 complexes, immunoassays were developed, optimized, and standardized [23, 24, 52]. The first immunoassay introduced was a two-site enzyme-linked immunosorbent assay (ELISA), for measuring antibodies to HPF4 [12]. The antigen, HPF4, is coated on the plate, which is then saturated and stabilized. A well-defined stoichiometric concentration of PF4 tetramer and heparin (about 150 μg heparin per mg PF4) must be used for presenting epitopes reactive with antibodies. Heparin-dependent antibodies can be caught from the diluted tested plasma or serum (usually a 1:100 dilution is used), during the first incubation step. Following a washing step, the immunoconjugate, specific for human immunoglobulins or their isotypes, is introduced, and a second incubation step is performed. The immunoconjugate is often a rabbit or goat antibody, specific for human whole immunoglobulins (IgGAM) or for only an isotype (IgG, IgA, or IgM), and labeled with peroxidase. In current practice, this tag reagent is an antihuman IgG-peroxidase conjugate. Following a new washing step, the substrate is introduced, and a color develops. Tetramethylbenzidine (TMB) with hydrogen peroxide (H2O2) is now the most often used substrate, producing a blue color, which turns yellow when the reaction is stopped with sulfuric acid. Absorbance is measured using a microplate reader at 450 nm. Different variant methods have been introduced. Heparin can be replaced with another sulfated polymer (electronegative) such as polyvinyl sulfonate. However, using heparin matches better with the context of antibody generation and in vivo pathogenicity. Magnetic latex particles can be used in place of the solid phase capture micro-ELISA. Different tag antibody labels can be used instead of peroxidase, such as alkaline phosphatase (with its appropriate substrate). The “enzyme-substrate” detection system with chemiluminescence or fluorescence can also be used (direct measurement). Combining latex magnetic particles and chemiluminescence or fluorescence allows immunoassay automation. Lastly, performing immunoassays in the presence of an excess of heparin allows confirming antibody specificity [25, 55].
Figure 6 shows the general immunoassay principle for detecting heparin-dependent antibodies. For testing the non-PF4 antigen-dependent antibodies, similar immunoassays can be designed by replacing PF4 with the concerned protein (e.g., IL8 or PrS). We developed an original patented approach, where heparin in excess is coated in the presence of PrS and remains biologically available. The tested patient’s sample is then incubated in the presence of a concentrated platelet lysate (containing all the platelet releasable proteins, but not plasma factors). If antibodies are present, a ternary complex is formed between tetrameric PF4 (or eventually another platelet protein), immobilized heparin, and antibodies. Caught antibodies are then detected as previously described [24]. This method offers a kinetic model for testing antibodies and mimics their binding to heparin-protein complexes bound onto platelet or blood cell surfaces. This assay reflects better the mechanisms occurring in pathology and offers improved and optimized sensitivity and specificity.
General principle of immunoassays used for heparin-dependent antibodies, either globally or for specific isotypes. Enzyme tag with substrate is used in ELISA. Chemiluminescent immunoassays, using magnetic latex particles, can be automated on immunological analyzers. Using heparin in excess in sample diluent allows confirming antibody specificity.
Functional assays rely on testing the capability of heparin-dependent antibodies to activate platelets at a low (0.1–1.0 IU/ml) and a high (10–100 IU/ml) heparin concentration. In HIT/HITT, platelets are only activated at the low heparin concentration. Functional assays need to use normal donor platelets, freshly prepared. They must be duly selected for the right reactivity. This is the constraint which limits the use of this technique. Platelets are used as platelet-rich plasma (PRP) or as washed platelets. What induces donor to donor responsiveness in platelet activation assays used for HIT antibodies is not totally understood. The CD32 platelet density or His polymorphism could favor reactivity. In practice, platelets need to be qualified with a known positive sample for their appropriateness. Frequently, platelets from four normal donors are used, and the assay is positive if at least two out of the four donors give a positive platelet activation test. Other factors can regulate platelet activity, and interestingly washed platelets are usually more reactive than PRP. This can be explained by some platelet activation induced by the washing process, and a higher amount of PF4 is present on platelet surface. Functional assays concern PAT, SRA, heparin-induced platelet activation (HIPA), and flow cytometric assays (FCA); but other assays have been reported and elegantly reviewed in 2017 [53]. PAT is a simple aggregation assay performed with PRP and the tested patient citrated plasma. SRA is performed with washed platelets labeled with C14, incubated with tested patient’s plasma, and released C14-serotonin is measured. HIPA is also performed with washed platelets, incubated with the tested sample, and platelet activation/aggregation is visually evaluated. FCA is a technique that requires to mix PRP (washed platelets are possible) with patient’s citrated plasma and to measure platelet activation through the expression of P-selectin [24]. FCA can also be used for the measurement of antibody-induced release of platelet microparticles. SRA is considered as the reference and most sensitive method. PAT has a poor sensitivity. HIPA needs trained laboratory operators and is mainly used in Germany and some neighboring countries. FCA is now a more standardized approach and looks promising but needs to be confirmed through practical experience in clinical laboratories. This method can be available in many centers for testing in emergency, provided a flow cytometer and fresh platelets are available.
The diagnosis of HIT/HITT must be done accurately and reliably for a safe management of concerned patients [25]. The first alert signal is thrombocytopenia occurring 5–15 days following the onset of heparin therapy or earlier if the patient had a previous exposure to that drug within the 3 preceding months. HIT, or HITT if thrombosis is present, is then suspected and must rapidly be confirmed. If this complication is excluded, patients can continue to receive heparin, the most effective anticoagulant in many critical clinical situations. If the disease is confirmed or cannot be excluded, or if HIT is suspected but the diagnosis cannot be conducted, heparin must be replaced by another anticoagulant, according to the clinical context and practitioners’ experience. Figure 7 shows an algorithm for establishing or excluding the diagnosis of HIT. When HIT is suspected, the pretest clinical probability must be evaluated with the 4Ts method or another one in use in the clinical setting [28]. The 4Ts score is simple and relatively well-standardized. When HIT/HITT is suspected, heparin is immediately stopped, and another anticoagulant is used to avoid any risk of severe complication. Nevertheless, the diagnosis must be established and confirmed, as the patient can need heparin later. The first laboratory investigation involves immunological testing for antibodies. If the test is negative, and the clinical probability is low or moderate, HIT can be excluded. But if clinical probability is high, HIT cannot be excluded and remains possible with non-PF4 heparin-dependent antigens involved. If positive, antibodies are present. HIT develops mainly when IgGs are generated and present at high concentration. Many authors consider that HIT occurs when the optical density (OD) in ELISA is >1.00 (the cutoff value for the positive range being at ≥0.5). When the IgG immunoassay is positive, a functional assay must be performed for confirming the diagnosis, as many heparin-dependent antibodies are asymptomatic. This functional assay must be as sensitive and specific as possible. In any case if clinical probability is high, the possibility of HIT complication remains present, whether the laboratory testing is. Testing must be repeated [56], and other antigens than HPF4 can be investigated.
Scheme showing the algorithm for the diagnosis of HIT/HITT: when suspected (thrombocytopenia and/or thrombosis), the disease diagnosis involves the clinical probability estimation and laboratory testing, first with immunoassay, which allows ruling out disease when not present, and then with a confirmatory functional assay.
HIT/HITT is associated with UFH or LMWH therapy, both drugs being sulfated polysaccharides. Other heparin-like anti-FXa anticoagulants, such as fondaparinux or danaparoid sodium, do not generate drug-specific antibodies [7, 10]. However, cross-reactivity of these drugs with antibodies present in patients with characterized HIT/HITT can be observed in laboratory assays [57]. This cross-reactivity has been reported for danaparoid sodium when it is tested in the immunoassay at a high concentration in the presence of PF4 (about 3.00 mg danaparoid sodium per mg of PF4). This can be due to the high-affinity heparan sulfate component present in this drug, which represents about 4% of the total. Cross-reactivity has also been reported in functional assays. However, there is no evidence that danaparoid sodium can generate drug-induced antibodies, and cross-reactivity is opposed by the other non-affinity components (about 80% low-affinity heparan sulfate, 12% dermatan sulfate, and 4% chondroitin sulfate), present in large excess, which disrupt the possible complexes formed, as do other low-sulfated polysaccharides [9, 58]. Therefore, there is no evidence that danaparoid sodium can provoke HIT/HITT, and the reported results and long-term clinical experience in many countries suggest that cross-reactivity is totally inhibited by the major non-affinity fractions. Furthermore, danaparoid sodium at therapeutic concentrations can inhibit the heparin-induced platelet aggregation. Conversely, pentosan polysulfate was found to be as effective as heparin and to form complexes with PF4 at similar ratios than UFH, for binding all heparin-dependent antibodies [8, 14]. Lastly, fondaparinux is not expected to induce drug-dependent antibodies or to cross-react with existing antibodies [32].
In this chapter we have reviewed the present understanding of the generation of heparin-dependent antibodies in UFH- or LMWH-treated patients, which are the primary cause for HIT/HITT and a major adverse effect of heparin therapy. This risk is much higher when UFH is used, and disease develops more frequently in some clinical situations including cardiac or orthopedic surgery, traumatology, or malignancy. The occurrence of HIT/HITT tends to decrease thanks to a better control of therapy with UFH, shorter treatment times, and the use of LMWH when possible. When heparin therapy needs to be stopped, a large panel of alternative anticoagulants is available, although in some applications heparin remains the most effective one.
The mechanisms, which can induce generation of heparin-dependent antibodies, and pathogenicity for some of them have been extensively described and discussed in literature [14, 19, 20, 22, 42, 46]. Immunization develops when defined concentrations of heparin and PF4, forming stoichiometric multimolecular complexes, are present. In vivo, immunogenic complexes with PF4 can also be formed with other polyanions such as polyphosphates [59]. Various isotypes can be generated, IgM, IgA, or IgG, but almost all clinical complications of this iatrogenic disease are reported with IgGs present at high concentration and with high affinity. For HIT/HITT pathological development, various patient-associated and fortuity factors are required. Stoichiometric HPF4 complexes must be present for stimulating the immune system and developing antibodies but also for expressing pathogenicity. Heparin-dependent antibodies are harmful only if they bind to target antigenic structures (mainly HPF4 stoichiometric complexes), present on platelets, ECs, or other blood cells, focusing the immunological response. The immune system is then deviated from its protective role and destroys the patient’s own cells [60].
HIT/HITT diagnosis is of essence for confirming or excluding this disease, and heparin treatment can be continued if the risk is ruled out. The first step when thrombocytopenia and/or thrombosis occur is to suspect this heparin adverse effect and to evaluate the pretest clinical probability. The 4Ts score is frequently used and allows risk classification from 0 to 8, 6–8 being the highest risk. Concomitantly, performing an immunoassay allows to detect and to measure IgG heparin-dependent antibodies targeted to HPF4. If the assay is negative and if clinical probability is low or moderate (score ≤ 5), HIT can be excluded, but patients need to be monitored closely, especially if thrombocytopenia is not corrected. If positive, IgG heparin-dependent antibodies are present, and HIT probability is higher if ELISA OD ≥ 1.00. Finally, the use of functional assays allows differentiating asymptomatic antibodies from those which can activate platelets and provoke disease. The presence of HIT or HITT is confirmed when the functional assay is positive [60]. However, even when negative, if clinical probability is high (6–8), HIT/HITT remains possible, and patients must be managed accordingly. Heparin cannot be continued in any patient with a possible or probable HIT diagnosis, and an alternative anticoagulant must be used.
The authors would like to thank the research groups with whom they had the opportunity and honor to collaborate and especially Profs. D. Meyer (Paris, France), A. Greinacher (Greifswald, Germany), T. Bakchoul (Tübingen, Germany), S. Panzer (Vienna, Austria), M. Poncz and G. Arepally (Philadelphia, USA), J. Fareed and J. Walenga (Chicago, USA), Y. Gruel and C. Pouplard (France), I. Elalamy (France), I. Gouin and P. Guéret (France), and all those who gave us the opportunity to investigate HIT.
IntechOpen books are indexed by the following abstracting and indexing services:
",metaTitle:"Indexing and Abstracting",metaDescription:"IntechOpen was built by scientists, for scientists. We understand the community we serve, but to bring an even better service to the table for IntechOpen Authors and Academic Editors, we partnered with the leading companies and associations in the industry and beyond.",metaKeywords:null,canonicalURL:"/page/indexing-and-abstracting",contentRaw:'[{"type":"htmlEditorComponent","content":"Clarivate Web Of Science - Book Citation Index
\\n\\nCroatian Library (digital NSK)
\\n\\nOCLC (Online Computer Library Center) - WorldCat® Digital Collection Gateway
\\n\\n\\n\\n
\\n"}]'},components:[{type:"htmlEditorComponent",content:'
Clarivate Web Of Science - Book Citation Index
\n\nCroatian Library (digital NSK)
\n\nOCLC (Online Computer Library Center) - WorldCat® Digital Collection Gateway
\n\n\n\n
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5766},{group:"region",caption:"Middle and South America",value:2,count:5227},{group:"region",caption:"Africa",value:3,count:1717},{group:"region",caption:"Asia",value:4,count:10367},{group:"region",caption:"Australia and Oceania",value:5,count:897},{group:"region",caption:"Europe",value:6,count:15789}],offset:12,limit:12,total:118188},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{topicId:"14"},books:[{type:"book",id:"10666",title:"Noble Metals Recent Advanced Studies and Applications",subtitle:null,isOpenForSubmission:!0,hash:"7322b325b1276e2b4185a7db798d588a",slug:null,bookSignature:"Dr. Mousumi Sen",coverURL:"https://cdn.intechopen.com/books/images_new/10666.jpg",editedByType:null,editors:[{id:"310218",title:"Dr.",name:"Mousumi",surname:"Sen",slug:"mousumi-sen",fullName:"Mousumi Sen"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10668",title:"Sustainable Concrete",subtitle:null,isOpenForSubmission:!0,hash:"55856c6a8bc3a5b21dae5a1af09a56b6",slug:null,bookSignature:"Prof. Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/10668.jpg",editedByType:null,editors:[{id:"144691",title:"Prof.",name:"Hosam",surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10669",title:"Corrosion",subtitle:null,isOpenForSubmission:!0,hash:"4a76d54f8a40fc2e7002a8d13fd617c1",slug:null,bookSignature:"Dr. Fahmina Zafar, Dr. Anujit Ghosal and Dr. Eram Sharmin",coverURL:"https://cdn.intechopen.com/books/images_new/10669.jpg",editedByType:null,editors:[{id:"89672",title:"Dr.",name:"Fahmina",surname:"Zafar",slug:"fahmina-zafar",fullName:"Fahmina Zafar"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10670",title:"Properties and Applications of Alginates",subtitle:null,isOpenForSubmission:!0,hash:"062083e53cc5c808af597de6426cea06",slug:null,bookSignature:"Dr. Irem Deniz, Dr. Esra Imamoglu and Dr. Tugba Keskin Gundogdu",coverURL:"https://cdn.intechopen.com/books/images_new/10670.jpg",editedByType:null,editors:[{id:"204855",title:"Dr.",name:"Irem",surname:"Deniz",slug:"irem-deniz",fullName:"Irem Deniz"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10941",title:"Ferrite",subtitle:null,isOpenForSubmission:!0,hash:"f6a323bfa4565d7c676bc3733b4983b0",slug:null,bookSignature:"Dr. Maaz Khan",coverURL:"https://cdn.intechopen.com/books/images_new/10941.jpg",editedByType:null,editors:[{id:"107765",title:"Dr.",name:"Maaz",surname:"Khan",slug:"maaz-khan",fullName:"Maaz Khan"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:16},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:4},{group:"topic",caption:"Business, Management and Economics",value:7,count:1},{group:"topic",caption:"Chemistry",value:8,count:8},{group:"topic",caption:"Computer and Information Science",value:9,count:6},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:7},{group:"topic",caption:"Engineering",value:11,count:16},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:3},{group:"topic",caption:"Materials Science",value:14,count:5},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:26},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:2},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:2},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:1}],offset:12,limit:12,total:5},popularBooks:{featuredBooks:[],offset:0,limit:12,total:null},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9671",title:"Macrophages",subtitle:null,isOpenForSubmission:!1,hash:"03b00fdc5f24b71d1ecdfd75076bfde6",slug:"macrophages",bookSignature:"Hridayesh Prakash",coverURL:"https://cdn.intechopen.com/books/images_new/9671.jpg",editors:[{id:"287184",title:"Dr.",name:"Hridayesh",middleName:null,surname:"Prakash",slug:"hridayesh-prakash",fullName:"Hridayesh Prakash"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10432",title:"Casting Processes and Modelling of Metallic Materials",subtitle:null,isOpenForSubmission:!1,hash:"2c5c9df938666bf5d1797727db203a6d",slug:"casting-processes-and-modelling-of-metallic-materials",bookSignature:"Zakaria Abdallah and Nada Aldoumani",coverURL:"https://cdn.intechopen.com/books/images_new/10432.jpg",editors:[{id:"201670",title:"Dr.",name:"Zak",middleName:null,surname:"Abdallah",slug:"zak-abdallah",fullName:"Zak Abdallah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7841",title:"New Insights Into Metabolic Syndrome",subtitle:null,isOpenForSubmission:!1,hash:"ef5accfac9772b9e2c9eff884f085510",slug:"new-insights-into-metabolic-syndrome",bookSignature:"Akikazu Takada",coverURL:"https://cdn.intechopen.com/books/images_new/7841.jpg",editors:[{id:"248459",title:"Dr.",name:"Akikazu",middleName:null,surname:"Takada",slug:"akikazu-takada",fullName:"Akikazu Takada"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editedByType:"Edited by",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editedByType:"Edited by",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editedByType:"Edited by",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8098",title:"Resources of Water",subtitle:null,isOpenForSubmission:!1,hash:"d251652996624d932ef7b8ed62cf7cfc",slug:"resources-of-water",bookSignature:"Prathna Thanjavur Chandrasekaran, Muhammad Salik Javaid, Aftab Sadiq",coverURL:"https://cdn.intechopen.com/books/images_new/8098.jpg",editedByType:"Edited by",editors:[{id:"167917",title:"Dr.",name:"Prathna",middleName:null,surname:"Thanjavur Chandrasekaran",slug:"prathna-thanjavur-chandrasekaran",fullName:"Prathna Thanjavur Chandrasekaran"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editedByType:"Edited by",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10432",title:"Casting Processes and Modelling of Metallic Materials",subtitle:null,isOpenForSubmission:!1,hash:"2c5c9df938666bf5d1797727db203a6d",slug:"casting-processes-and-modelling-of-metallic-materials",bookSignature:"Zakaria Abdallah and Nada Aldoumani",coverURL:"https://cdn.intechopen.com/books/images_new/10432.jpg",editedByType:"Edited by",editors:[{id:"201670",title:"Dr.",name:"Zak",middleName:null,surname:"Abdallah",slug:"zak-abdallah",fullName:"Zak Abdallah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9671",title:"Macrophages",subtitle:null,isOpenForSubmission:!1,hash:"03b00fdc5f24b71d1ecdfd75076bfde6",slug:"macrophages",bookSignature:"Hridayesh Prakash",coverURL:"https://cdn.intechopen.com/books/images_new/9671.jpg",editedByType:"Edited by",editors:[{id:"287184",title:"Dr.",name:"Hridayesh",middleName:null,surname:"Prakash",slug:"hridayesh-prakash",fullName:"Hridayesh Prakash"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8415",title:"Extremophilic Microbes and Metabolites",subtitle:"Diversity, Bioprospecting and Biotechnological Applications",isOpenForSubmission:!1,hash:"93e0321bc93b89ff73730157738f8f97",slug:"extremophilic-microbes-and-metabolites-diversity-bioprospecting-and-biotechnological-applications",bookSignature:"Afef Najjari, Ameur Cherif, Haïtham Sghaier and Hadda Imene Ouzari",coverURL:"https://cdn.intechopen.com/books/images_new/8415.jpg",editedByType:"Edited by",editors:[{id:"196823",title:"Dr.",name:"Afef",middleName:null,surname:"Najjari",slug:"afef-najjari",fullName:"Afef Najjari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9731",title:"Oxidoreductase",subtitle:null,isOpenForSubmission:!1,hash:"852e6f862c85fc3adecdbaf822e64e6e",slug:"oxidoreductase",bookSignature:"Mahmoud Ahmed Mansour",coverURL:"https://cdn.intechopen.com/books/images_new/9731.jpg",editedByType:"Edited by",editors:[{id:"224662",title:"Prof.",name:"Mahmoud Ahmed",middleName:null,surname:"Mansour",slug:"mahmoud-ahmed-mansour",fullName:"Mahmoud Ahmed Mansour"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"1028",title:"Hemodynamics",slug:"hemodynamics",parent:{title:"Hematology",slug:"hematology"},numberOfBooks:2,numberOfAuthorsAndEditors:16,numberOfWosCitations:12,numberOfCrossrefCitations:2,numberOfDimensionsCitations:7,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"hemodynamics",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"7042",title:"Highlights on Hemodynamics",subtitle:null,isOpenForSubmission:!1,hash:"ab4cb86baa2cadb67630b31257cb04b2",slug:"highlights-on-hemodynamics",bookSignature:"Theodoros Aslanidis",coverURL:"https://cdn.intechopen.com/books/images_new/7042.jpg",editedByType:"Edited by",editors:[{id:"200252",title:"Dr.",name:"Theodoros",middleName:null,surname:"Aslanidis",slug:"theodoros-aslanidis",fullName:"Theodoros Aslanidis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1653",title:"Hemodynamics",subtitle:"New Diagnostic and Therapeutic Approaches",isOpenForSubmission:!1,hash:"2cf4b686414a77f0c867007f5062914f",slug:"hemodynamics-new-diagnostic-and-therapeutic-approaches",bookSignature:"A. Seda Artis",coverURL:"https://cdn.intechopen.com/books/images_new/1653.jpg",editedByType:"Edited by",editors:[{id:"99453",title:"Dr.",name:"Aise Seda",middleName:null,surname:"Artis",slug:"aise-seda-artis",fullName:"Aise Seda Artis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:2,mostCitedChapters:[{id:"36116",doi:"10.5772/36263",title:"The Evaluation of Renal Hemodynamics with Doppler Ultrasonography",slug:"the-evaluation-of-renal-hemodynamics-with-renal-doppler-ultrasonography",totalDownloads:11001,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"hemodynamics-new-diagnostic-and-therapeutic-approaches",title:"Hemodynamics",fullTitle:"Hemodynamics - New Diagnostic and Therapeutic Approaches"},signatures:"Mahir Kaya",authors:[{id:"107675",title:"Dr.",name:"Mahir",middleName:null,surname:"Kaya",slug:"mahir-kaya",fullName:"Mahir Kaya"}]},{id:"36121",doi:"10.5772/34272",title:"Carnosine and Its Role on the Erythrocyte Rheology",slug:"carnosine-and-its-role-on-the-erythrocyte-rheology",totalDownloads:1872,totalCrossrefCites:0,totalDimensionsCites:2,book:{slug:"hemodynamics-new-diagnostic-and-therapeutic-approaches",title:"Hemodynamics",fullTitle:"Hemodynamics - New Diagnostic and Therapeutic Approaches"},signatures:"A. Seda Artis and Sami Aydogan",authors:[{id:"99453",title:"Dr.",name:"Aise Seda",middleName:null,surname:"Artis",slug:"aise-seda-artis",fullName:"Aise Seda Artis"},{id:"110016",title:"Prof.",name:"Sami",middleName:null,surname:"Aydogan",slug:"sami-aydogan",fullName:"Sami Aydogan"}]},{id:"36119",doi:"10.5772/36876",title:"How Ozone Treatment Affects Erythrocytes",slug:"how-ozone-treatment-affects-erythrocytes",totalDownloads:3902,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"hemodynamics-new-diagnostic-and-therapeutic-approaches",title:"Hemodynamics",fullTitle:"Hemodynamics - New Diagnostic and Therapeutic Approaches"},signatures:"Sami Aydogan and A. Seda Artis",authors:[{id:"99453",title:"Dr.",name:"Aise Seda",middleName:null,surname:"Artis",slug:"aise-seda-artis",fullName:"Aise Seda Artis"},{id:"110016",title:"Prof.",name:"Sami",middleName:null,surname:"Aydogan",slug:"sami-aydogan",fullName:"Sami Aydogan"}]}],mostDownloadedChaptersLast30Days:[{id:"62838",title:"Introductory Chapter: Hemodynamic Management. The Problem of Monitoring Choice",slug:"introductory-chapter-hemodynamic-management-the-problem-of-monitoring-choice",totalDownloads:537,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"highlights-on-hemodynamics",title:"Highlights on Hemodynamics",fullTitle:"Highlights on Hemodynamics"},signatures:"Theodoros Aslanidis",authors:[{id:"200252",title:"Dr.",name:"Theodoros",middleName:null,surname:"Aslanidis",slug:"theodoros-aslanidis",fullName:"Theodoros Aslanidis"}]},{id:"36119",title:"How Ozone Treatment Affects Erythrocytes",slug:"how-ozone-treatment-affects-erythrocytes",totalDownloads:3900,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"hemodynamics-new-diagnostic-and-therapeutic-approaches",title:"Hemodynamics",fullTitle:"Hemodynamics - New Diagnostic and Therapeutic Approaches"},signatures:"Sami Aydogan and A. Seda Artis",authors:[{id:"99453",title:"Dr.",name:"Aise Seda",middleName:null,surname:"Artis",slug:"aise-seda-artis",fullName:"Aise Seda Artis"},{id:"110016",title:"Prof.",name:"Sami",middleName:null,surname:"Aydogan",slug:"sami-aydogan",fullName:"Sami Aydogan"}]},{id:"36116",title:"The Evaluation of Renal Hemodynamics with Doppler Ultrasonography",slug:"the-evaluation-of-renal-hemodynamics-with-renal-doppler-ultrasonography",totalDownloads:10998,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"hemodynamics-new-diagnostic-and-therapeutic-approaches",title:"Hemodynamics",fullTitle:"Hemodynamics - New Diagnostic and Therapeutic Approaches"},signatures:"Mahir Kaya",authors:[{id:"107675",title:"Dr.",name:"Mahir",middleName:null,surname:"Kaya",slug:"mahir-kaya",fullName:"Mahir Kaya"}]},{id:"62847",title:"Cerebral Hemodynamics in Pediatric Hydrocephalus: Evaluation by Means of Transcranial Doppler Sonography",slug:"cerebral-hemodynamics-in-pediatric-hydrocephalus-evaluation-by-means-of-transcranial-doppler-sonogra",totalDownloads:455,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"highlights-on-hemodynamics",title:"Highlights on Hemodynamics",fullTitle:"Highlights on Hemodynamics"},signatures:"Branislav Kolarovszki",authors:[{id:"92436",title:"Associate Prof.",name:"Branislav",middleName:null,surname:"Kolarovszki",slug:"branislav-kolarovszki",fullName:"Branislav Kolarovszki"}]},{id:"63370",title:"Functioning of the Cardiovascular System of Women in Different Phases of the Ovarian-Menstrual Cycle",slug:"functioning-of-the-cardiovascular-system-of-women-in-different-phases-of-the-ovarian-menstrual-cycle",totalDownloads:389,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"highlights-on-hemodynamics",title:"Highlights on Hemodynamics",fullTitle:"Highlights on Hemodynamics"},signatures:"Olena Lutsenko",authors:[{id:"225667",title:"Mrs.",name:"Olena Ivanivna",middleName:null,surname:"Lutsenko",slug:"olena-ivanivna-lutsenko",fullName:"Olena Ivanivna Lutsenko"}]},{id:"62523",title:"Influence of Branching Patterns and Active Contractions of the Villous Tree on Fetal and Maternal Blood Circulations in the Human Placenta",slug:"influence-of-branching-patterns-and-active-contractions-of-the-villous-tree-on-fetal-and-maternal-bl",totalDownloads:339,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"highlights-on-hemodynamics",title:"Highlights on Hemodynamics",fullTitle:"Highlights on Hemodynamics"},signatures:"Yoko Kato",authors:[{id:"249827",title:"Prof.",name:"Yoko",middleName:null,surname:"Kato",slug:"yoko-kato",fullName:"Yoko Kato"}]},{id:"36122",title:"Soluble Guanylate Cyclase Modulators in Heart Failure",slug:"soluble-guanylate-cyclase-modulators-in-heart-failure",totalDownloads:1598,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"hemodynamics-new-diagnostic-and-therapeutic-approaches",title:"Hemodynamics",fullTitle:"Hemodynamics - New Diagnostic and Therapeutic Approaches"},signatures:"Veselin Mitrovic and Stefan Lehinant",authors:[{id:"111559",title:"Dr.",name:"Stefan",middleName:null,surname:"Lehinant",slug:"stefan-lehinant",fullName:"Stefan Lehinant"}]},{id:"62149",title:"3D Numerical Study of Metastatic Tumor Blood Perfusion and Interstitial Fluid Flow Based on Microvasculature Response to Inhibitory Effect of Angiostatin",slug:"3d-numerical-study-of-metastatic-tumor-blood-perfusion-and-interstitial-fluid-flow-based-on-microvas",totalDownloads:356,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"highlights-on-hemodynamics",title:"Highlights on Hemodynamics",fullTitle:"Highlights on Hemodynamics"},signatures:"Gaiping Zhao",authors:[{id:"172001",title:"Ph.D.",name:"Gaiping",middleName:null,surname:"Zhao",slug:"gaiping-zhao",fullName:"Gaiping Zhao"}]},{id:"36118",title:"Hemodynamics Study Based on Near-Infrared Optical Assessment",slug:"hemodynamics-study-based-on-near-infrared-optical-assessment",totalDownloads:2352,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"hemodynamics-new-diagnostic-and-therapeutic-approaches",title:"Hemodynamics",fullTitle:"Hemodynamics - New Diagnostic and Therapeutic Approaches"},signatures:"Chia-Wei Sun and Ching-Cheng Chuang",authors:[{id:"116138",title:"Dr",name:"Chia-Wei",middleName:null,surname:"Sun",slug:"chia-wei-sun",fullName:"Chia-Wei Sun"}]},{id:"36120",title:"Regulation of Renal Hemodyamics by Purinergic Receptors in Angiotensin II -Induced Hypertension",slug:"regulation-of-renal-hemodynamics-by-purinergic-receptors-in-angiotensin-ii-induced-hypertension",totalDownloads:1323,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"hemodynamics-new-diagnostic-and-therapeutic-approaches",title:"Hemodynamics",fullTitle:"Hemodynamics - New Diagnostic and Therapeutic Approaches"},signatures:"Martha Franco, Rocío Bautista-Pérez and Oscar Pérez-Méndez",authors:[{id:"113134",title:"Dr.",name:"Martha",middleName:null,surname:"Franco",slug:"martha-franco",fullName:"Martha Franco"}]}],onlineFirstChaptersFilter:{topicSlug:"hemodynamics",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/318960/zulfiqar-ali-gurmani",hash:"",query:{},params:{id:"318960",slug:"zulfiqar-ali-gurmani"},fullPath:"/profiles/318960/zulfiqar-ali-gurmani",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()